Proton-pump inhibitor use and the risk for community-acquired pneumonia

被引:207
|
作者
Sarkar, Monika [1 ]
Hennessy, Sean [1 ]
Yang, Yu-Xiao [1 ]
机构
[1] Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-149-6-200809160-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). Objective: To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. Design: Nested case-control study. Setting: The General Practice Research Database (1987 to 2002) in the United Kingdom. Participants: Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up in the database. Case patients (n = 80 066) were defined as those who received an incident diagnosis of CAP. Control participants (n = 799 881) were selected by using incidence density sampling, matching on practice site, calendar period, and follow-up duration. Measurements: Use of PPIs within 30 days before the index date. Adjusted odds ratios (ORs) were estimated by using conditional logistic regression, adjusting for potential confounders. Results: Overall, current PPI use was not associated with an increased risk for CAP (adjusted OR, 1.02 [95% CI, 0.97 to 1.08]) or risk for CAP that required hospitalization (adjusted OR, 1.01 [CI, 0.91 to 1.12]). There was a strong increase in risk for CAP associated with current use of PPI therapy that was started within the previous 2 days (adjusted OR, 6.53 [CI, 3.95 to 10.80]), 7 days (adjusted OR, 3.79 [CI, 2.66 to 5.42]), and 14 days (adjusted OR, 3.21 [CI, 2.46 to 4.18]), but there was no statistically significant association for longer-term current PPI therapy. A separate matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]). Limitations: Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP. Conclusion: Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.
引用
收藏
页码:391 / W75
页数:10
相关论文
共 50 条
  • [41] Community-acquired pneumonia: risk and prognosis
    Nalibaeva, Rano
    Liverko, Irina
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [42] The risk stratification in community-acquired pneumonia
    Ozlek, Eda
    Biteker, Funda Sungur
    Cil, Cem
    Celik, Oguzhan
    Ozlek, Bulent
    Dogan, Volkan
    Biteker, Murat
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2019, 37 (01): : 171 - 171
  • [43] PPI use is associated with an increased risk of community-acquired pneumonia
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (9): : 475 - 475
  • [44] Pharmacotherapy and the risk for community-acquired pneumonia
    Jen-Tzer Gau
    Utkarsh Acharya
    Salman Khan
    Victor Heh
    Lona Mody
    Tzu-Cheg Kao
    BMC Geriatrics, 10
  • [45] The Risk of Corticosteroids in Community-Acquired Pneumonia
    Buell, Kevin G.
    Lander, Eric M.
    AMERICAN FAMILY PHYSICIAN, 2020, 101 (04) : 197 - 197
  • [46] Use of ACE inhibitors and risk of community-acquired pneumonia: a review
    Petros I. Rafailidis
    Dimitrios K. Matthaiou
    Ioannis Varbobitis
    Matthew E. Falagas
    European Journal of Clinical Pharmacology, 2008, 64 : 565 - 573
  • [47] Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
    Filion, Kristian B.
    Chateau, Dan
    Targownik, Laura E.
    Gershon, Andrea
    Durand, Madeleine
    Tamim, Hala
    Teare, Gary F.
    Ravani, Pietro
    Ernst, Pierre
    Dormuth, Colin R.
    GUT, 2014, 63 (04) : 552 - 558
  • [48] Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis
    Giuliano, Christopher
    Wilhelm, Sheila M.
    Kale-Pradhan, Pramodini B.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (03) : 337 - 345
  • [49] Gitelman syndrome triggered by proton-pump inhibitor use
    Tursi, Antonio
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (06) : 911 - 911
  • [50] Are proton-pump inhibitors (PPIs) associated with an increased risk of community-acquired pneumonia (CAP)? A nested case-control study investigating recent PPI exposure and CAP
    Sarkar, Monika A.
    Hennessy, Sean
    Yang, Yu-Xiao
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S446 - S446